WALTHAM, Mass., November 1, 2021 – Conjugate Group, a flexible drug development service provider to the biopharma industry, has been engaged by an early-stage Immuno-Oncology company pioneering the next generation of immunotherapies to provide a tactical team of consultants and Subject Matter Experts in order to file their first IND. Conjugate Group will provide Clinical Development and Operations, CMC, Regulatory Affairs, DMPK, Quality Assurance, Medical Writing, and Pharmacovigilance resources to plan, produce, and file their application for a first-in-human clinical study. We look forward to assisting this client in advancing a novel form of cancer therapy, and in gathering critical human data.

About The Conjugate Group

Founded in 2017, Conjugate Group provides flexible resources to clients in the biopharmaceutical industry, with a focus on the clinical development lifecycle. A leader in Consulting and Contract Services, we offer individual resources, full-function outsourcing, and milestone focused tactical teams to help our clients operate effectively and efficiently.  We have helped numerous companies move products into and through the Clinic, from initial IND through registration and commercial launch.